tickdelta
tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

BMYBristol Myers Squibb

Health care · Pharmaceuticals · NYSE

Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. 10-K, Item 1

BMY quote by TradingView
Employees
32,500
Headquarters
Princeton, NJ
CEO
Christopher S. Boerner
Next results
around Feb 4, 2027
Compare with peers → Embed
All key numbers (37, from the latest 10-K and 10-Q) From EDGAR
EPS (ttm)4.51Sales (ttm)50.0BNet income (ttm)9.2BSales growth-0.2%EPS growth-Sales Q/Q+6.9%
Free cash flow9.3BGross margin69.2%Oper. margin-Net margin18.5%FCF margin18.6%ROE39.5%
ROA10.4%R&D / sales20.6%Dividend2.49Debt/Eq1.86Curr. ratio1.59Cash9.6B
Op. cash flow (ttm)10.7BNet debt34.1BQuick ratio1.44Payout ratio72.0%Tax rate24.4%Stock pay / sales1.1%
Shares out.2.0BShares Y/Y+0.6%Book / share11.45Cash / share4.68Sales / share24.48Asset turnover0.56
Inventory turns5.18Days sales out.73Sales 3Y CAGR+1.4%Sales 5Y CAGR+2.5%EPS 3Y CAGR+5.5%Employees32,500
Sales / employee1.5M

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Changes in the numbers

FY2025 against FY2024
  • Revenue growth slowed to -0.2%+7.3% → -0.2% · Revenue FY2025 / revenue FY2024 − 1, against the same a year earlier · 10-K ↗
  • Net income turned to a profit−$8.9B → $7.1B · Net income attributable to the company · 10-K ↗
What management wrote about it → · Every company →

BMY against Health care peers

Ten years, side by side → · All 60 →
GrowthProfitBalanceCleanInsiders
BMYPeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.

Sales growth
-0.2%54th of 60 · median +7.1%
Net margin
18.5%15th of 60 · median 9.6%
Return on equity
39.5%6th of 54 · median 13.1%
Free cash flow margin
18.6%21st of 56 · median 15.5%
Debt / equity (less is better)
1.8644th of 49 · median 0.66
BMY and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthGross marginNet marginROEFCF marginDebt / equity
BMY Bristol Myers Squibb$50.0B -0.2%69.2%18.5%39.5%18.6%1.86
PFE Pfizer$63.6B -1.6%73.4%6.3%4.5%18.5%0.70
ABT Abbott Laboratories$48.2B +5.7%56.9%9.7%9.2%14.0%0.61
TMO Thermo Fisher Scientific$47.4B +3.9%-14.9%12.9%16.0%0.79
AMGN Amgen$38.9B +10.0%70.9%24.1%65.4%24.6%3.76
MDT Medtronic$37.5B +8.4%65.0%13.9%10.4%16.3%0.56

From $46.4B of sales to $7.0B of profit

FY2021, from the 10-K income statement
Revenue to Gross profit: $36.4BRevenue to Cost of revenue: $9.9BGross profit to Net profit: $7.0BGross profit to Costs, tax, other: $29.5B Revenue: $46.4B Revenue$46.4B +9% Y/Y Gross profit: $36.4B · 79% margin Gross profit$36.4B79% margin Cost of revenue: $9.9B · 21% of revenue Cost of revenue$9.9B21% of revenue Net profit: $7.0B · 15% margin Net profit$7.0B15% margin Costs, tax, other: $29.5B · 63% of revenue Costs, tax, other$29.5B63% of revenue

Swipe sideways for the whole flow →

From $46.2B of sales to $6.3B of profit

FY2022, from the 10-K income statement and revenue by region
United States to Revenue: $31.5BInternational to Revenue: $13.8BOther to Revenue: $834.0MRevenue to Gross profit: $36.0BRevenue to Cost of revenue: $10.1BGross profit to Net profit: $6.3BGross profit to Costs, tax, other: $29.7B United States: $31.5B · 68% United States$31.5B68% International: $13.8B · 30% International$13.8B30% Other: $834.0M · 2% Other$834.0M2% Revenue: $46.2B Revenue$46.2B +0% Y/Y Gross profit: $36.0B · 78% margin Gross profit$36.0B78% margin Cost of revenue: $10.1B · 22% of revenue Cost of revenue$10.1B22% of revenue Net profit: $6.3B · 14% margin Net profit$6.3B14% margin −10% Y/Y Costs, tax, other: $29.7B · 64% of revenue Costs, tax, other$29.7B64% of revenue

Swipe sideways for the whole flow →

From $45.0B of sales to $8.0B of profit

FY2023, from the 10-K income statement and revenue by region
United States to Revenue: $31.2BInternational to Revenue: $13.1BOther to Revenue: $699.0MRevenue to Gross profit: $34.3BRevenue to Cost of revenue: $10.7BGross profit to Net profit: $8.0BGross profit to Costs, tax, other: $26.3B United States: $31.2B · 69% United States$31.2B69% International: $13.1B · 29% International$13.1B29% Other: $699.0M · 2% Other$699.0M2% Revenue: $45.0B Revenue$45.0B −2% Y/Y Gross profit: $34.3B · 76% margin Gross profit$34.3B76% margin Cost of revenue: $10.7B · 24% of revenue Cost of revenue$10.7B24% of revenue Net profit: $8.0B · 18% margin Net profit$8.0B18% margin +27% Y/Y Costs, tax, other: $26.3B · 58% of revenue Costs, tax, other$26.3B58% of revenue

Swipe sideways for the whole flow →

From $48.2B of sales to $7.1B of profit

FY2025, from the 10-K income statement and revenue by region
United States to Revenue: $33.3BInternational to Revenue: $13.8BOther to Revenue: $1.1BRevenue to Gross profit: $34.3BRevenue to Cost of revenue: $13.9BGross profit to Net profit: $7.1BGross profit to Costs, tax, other: $27.2B United States: $33.3B · 69% United States$33.3B69% International: $13.8B · 29% International$13.8B29% Other: $1.1B · 2% Other$1.1B2% Revenue: $48.2B Revenue$48.2B +0% Y/Y Gross profit: $34.3B · 71% margin Gross profit$34.3B71% margin Cost of revenue: $13.9B · 29% of revenue Cost of revenue$13.9B29% of revenue Net profit: $7.1B · 15% margin Net profit$7.1B15% margin Costs, tax, other: $27.2B · 56% of revenue Costs, tax, other$27.2B56% of revenue

Swipe sideways for the whole flow →

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2025
  • Cost of revenue
  • Costs, tax, other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →

Profitability

2 of 3
  • ✓
    Net margin above the peer median18.5% vs 9.6%
  • ✓
    Return on equity above 15%39.5%
  • !
    A profit in 8 of 10 years
Net margin, FY2016 to FY2025: 22.9% → 14.6%

Balance sheet

1 of 3
  • !
    Debt larger than equityDebt / equity 1.86 on the latest balance sheet (peer median 0.66)
  • ✓
    Current assets cover current liabilitiesCurrent ratio 1.59
  • !
    Net debt over 3 years of free cash flow$33.6B net debt, 3.6 years
Debt / equity at each year end, FY2016 to FY2025: 0.41 → 2.55
What the debt is made of ↓

Cash and shareholders

4 of 4
  • ✓
    Free cash flow positive in every one of 10 years$12.8B last year
  • ✓
    Share count down over 5 years−9.7%
  • ✓
    Dividend per share up over 5 years$1.84 → $2.49
  • ✓
    Cash from operations above net income$14.2B vs $7.1B
Free cash flow, FY2016 to FY2025: 1.8B → 12.8B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

What the debt is made of, and when it is due

balance sheet of Sep 30, 2026 · schedule of Dec 31, 2025
Debt: $43.6B Debt$43.6B Long-term debt: $41.8B · 96% Long-term debt$41.8B · 96% Due within a year: $768.0M · 2% Due within a year$768.0M · 2% Short-term borrowings: $1.0B · 2% Short-term borrowings$1.0B · 2% Next 12 months: $2.0B · 5% Next 12 months$2.0B · 5% Year 2: $2.0B · 5% Year 2$2.0B · 5% Year 3: $544.0M · 1% Year 3$544.0M · 1% Year 4: $2.2B · 5% Year 4$2.2B · 5% Year 5: $2.1B · 5% Year 5$2.1B · 5%

The debt note's own lines, 2025-12-31

Fixed rate $0Floating $500.0M Not stated $52.5B

Line, as the company names itKindRateFixed or floatingAmount
3.200% To 6.875% For Notes Due 2026 To 2097Notes and bonds–not stated$8.7B
4.250% Notes due 2049Notes and bonds4.25%not stated$3.8B
5.550% Notes due 2054Notes and bonds5.55%not stated$2.8B
5.200% Notes due 2034Notes and bonds5.20%not stated$2.5B
3.700% Notes due 2052Notes and bonds3.70%not stated$2.0B
4.125% Notes due 2039Notes and bonds4.12%not stated$2.0B
2.950% Notes due 2032Notes and bonds2.95%not stated$1.8B
2.550% Notes due 2050Notes and bonds2.55%not stated$1.5B
3.400% Notes due 2029Notes and bonds3.40%not stated$1.4B
4.581% Euro Notes due 2055Notes and bonds4.58%not stated$1.4B
3.363% Euro Notes due 2033Notes and bonds3.36%not stated$1.4B
3.857% Euro Notes due 2038Notes and bonds3.86%not stated$1.4B
4.550% Notes due 2048Notes and bonds4.55%not stated$1.3B
1.450% Notes due 2030Notes and bonds1.45%not stated$1.2B
3.550% Notes due 2042Notes and bonds3.55%not stated$1.2B
4.350% Notes due 2047Notes and bonds4.35%not stated$1.2B
5.100% Notes due 2031Notes and bonds5.10%not stated$1.2B
3.200% Notes due 2026Notes and bonds3.20%not stated$1.2B
1.125% Notes due 2027Notes and bonds1.12%not stated$1.0B
3.900% Notes due 2062Notes and bonds3.90%not stated$1.0B
5.750% Notes due 2031Notes and bonds5.75%not stated$1.0B
2.973% Notes due 2030Notes and bonds2.97%not stated$881.0M
4.289% Notes due 2045Notes and bonds4.29%not stated$881.0M
5.000% Notes due 2045Notes and bonds5.00%not stated$758.0M
2.350% Notes due 2040Notes and bonds2.35%not stated$750.0M
5.900% Notes due 2033Notes and bonds5.90%not stated$750.0M
4.625% Notes due 2044Notes and bonds4.62%not stated$748.0M
4.900% Notes due 2029Notes and bonds4.90%not stated$727.0M
1.750% Euro Notes due 2035Notes and bonds1.75%not stated$676.0M
3.900% Notes due 2028Notes and bonds3.90%not stated$544.0M
3.450% Notes due 2027Notes and bonds3.45%not stated$534.0M
3.250% Notes due 2027Notes and bonds3.25%not stated$512.0M
3.250% Notes due 2042Notes and bonds3.25%not stated$500.0M
5.500% Notes due 2044Notes and bonds5.50%not stated$500.0M
Floating Rate Notes due 2026Notes and bonds–floating$500.0M
5.650% Notes due 2064Notes and bonds5.65%not stated$440.0M
6.250% Notes due 2053Notes and bonds6.25%not stated$439.0M
6.400% Notes due 2063Notes and bonds6.40%not stated$371.0M
4.500% Notes due 2044Notes and bonds4.50%not stated$342.0M
5.875% Notes due 2036Notes and bonds5.88%not stated$279.0M
6.800% Notes due 2026Notes and bonds6.80%not stated$256.0M
5.250% Notes due 2043Notes and bonds5.25%not stated$226.0M
6.125% Notes due 2038Notes and bonds6.12%not stated$219.0M
5.700% Notes due 2040Notes and bonds5.70%not stated$153.0M
6.875% Notes due 2097Notes and bonds6.88%not stated$56.0M
All 45 lines

From the debt note in the 10-K's XBRL (0000014272-26-000004), as the company tags it: by issue, by year, by currency or by kind. Lines from two ways of cutting the same debt can overlap, so they are not added up. Fixed or floating is read from the line's own name only; "not stated" when it says neither.

Left: the debt lines on the balance sheet (XBRL). Right: the principal due each year, from the debt note's maturity schedule; it can differ a little from the balance sheet, which shows the debt net of discounts and fees. Leases are not counted. The full schedule →

Revenue and net income, FY2016 to FY2025

Revenue 48.2B Net income 7.1B
FY2016 revenue 19.4B · Revenues, 0000014272-19-000047 FY2016 net income 4.5B · NetIncomeLoss, 0000014272-19-000047 19.4B FY2016 FY2017 revenue 20.8B · Revenues, 0000014272-20-000082 FY2017 net income 1.0B · NetIncomeLoss, 0000014272-20-000082 20.8B FY2017 FY2018 revenue 22.6B · Revenues, 0000014272-21-000066 FY2018 net income 4.9B · NetIncomeLoss, 0000014272-21-000066 22.6B FY2018 FY2019 revenue 26.1B · Revenues, 0000014272-22-000051 FY2019 net income 3.4B · NetIncomeLoss, 0000014272-22-000051 26.1B FY2019 FY2020 revenue 42.5B · Revenues, 0000014272-23-000046 FY2020 net income -9.0B · NetIncomeLoss, 0000014272-23-000046 42.5B FY2020 FY2021 revenue 46.4B · Revenues, 0000014272-24-000044 FY2021 net income 7.0B · NetIncomeLoss, 0000014272-24-000044 46.4B FY2021 FY2022 revenue 46.2B · Revenues, 0000014272-25-000039 FY2022 net income 6.3B · NetIncomeLoss, 0000014272-25-000039 46.2B FY2022 FY2023 revenue 45.0B · Revenues, 0000014272-26-000004 FY2023 net income 8.0B · NetIncomeLoss, 0000014272-26-000004 45.0B FY2023 FY2024 revenue 48.3B · Revenues, 0000014272-26-000004 FY2024 net income -8.9B · NetIncomeLoss, 0000014272-26-000004 48.3B FY2024 FY2025 revenue 48.2B · Revenues, 0000014272-26-000004 FY2025 net income 7.1B · NetIncomeLoss, 0000014272-26-000004 48.2B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

BMY's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly
Revenue48.2B
FY2016: 19.4BFY2017: 20.8BFY2018: 22.6BFY2019: 26.1BFY2020: 42.5BFY2021: 46.4BFY2022: 46.2BFY2023: 45.0BFY2024: 48.3BFY2025: 48.2B FY2017FY2019FY2021FY2023FY2025
Net income7.1B
FY2016: 4.5BFY2017: 1.0BFY2018: 4.9BFY2019: 3.4BFY2020: -9.0BFY2021: 7.0BFY2022: 6.3BFY2023: 8.0BFY2024: -8.9BFY2025: 7.1B FY2017FY2019FY2021FY2023FY2025
Free cash flow12.8B
FY2016: 1.8BFY2017: 4.2BFY2018: 6.1BFY2019: 7.4BFY2020: 13.3BFY2021: 15.2BFY2022: 11.9BFY2023: 12.7BFY2024: 13.9BFY2025: 12.8B FY2017FY2019FY2021FY2023FY2025
EPS (diluted)3.46
FY2016: 2.65FY2017: 0.61FY2018: 3.01FY2019: 2.01FY2020: -3.99FY2021: 3.12FY2022: 2.95FY2023: 3.86FY2024: -4.41FY2025: 3.46 FY2017FY2019FY2021FY2023FY2025
Dividend per share2.49
FY2016: 1.53FY2017: 1.57FY2018: 1.61FY2019: 1.68FY2020: 1.84FY2021: 2.01FY2022: 2.19FY2023: 2.31FY2024: 2.42FY2025: 2.49 FY2017FY2019FY2021FY2023FY2025
Diluted shares2.0B
FY2016: 1.7BFY2017: 1.7BFY2018: 1.6BFY2019: 1.7BFY2020: 2.3BFY2021: 2.2BFY2022: 2.1BFY2023: 2.1BFY2024: 2.0BFY2025: 2.0B FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Gross product sales 88.1B182.8% +5.3%
Net product sales 46.8B97.0% 0.0%
Growth Portfolio 26.4B54.8% +17.0%
Legacy Portfolio 21.8B45.2% -15.4%
Eliquis 14.4B30.0% +8.3%
Opdivo 10.0B20.9% +8.0%
Orencia 3.7B7.7% +0.6%
Revlimid 3.0B6.1% -48.9%
Yervoy 2.9B6.0% +14.6%
Pomalyst/Imnovid 2.7B5.7% -22.9%
Reblozyl 2.3B4.8% +31.2%
Other Growth products 1.9B4.0% +17.1%
Alliance and other revenues 1.4B3.0% -5.5%
Breyanzi 1.4B2.8% +81.8%
Opdualag 1.2B2.5% +27.7%
Camzyos 1.1B2.2% +77.4%
Other revenues 992.0M2.1% -4.9%
Other Legacy products 798.0M1.7% -13.7%
Zeposia 577.0M1.2% +1.9%
Sprycel 493.0M1.0% -61.7%
Alliance revenues 447.0M0.9% -6.7%
Abecma 427.0M0.9% +5.2%
Abraxane 368.0M0.8% -57.9%
Sotyktu 291.0M0.6% +18.3%
Opdivo Qvantig 238.0M0.5% -
Krazati 205.0M0.4% +62.7%
Cobenfy 155.0M0.3% +1450%

10-K 0000014272-26-000004, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States 33.3B69.1% -2.4%
International 13.8B28.7% +4.8%
Other 1.1B2.3% +9.1%

10-K 0000014272-26-000004, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue19.4B20.8B22.6B26.1B42.5B46.4B46.2B45.0B48.3B48.2B
Cost of revenue5.0B6.0B6.5B8.1B11.8B9.9B10.1B10.7B14.0B13.9B
Gross profit14.5B14.7B16.1B18.1B30.7B-----
R&D5.0B6.5B6.3B6.1B10.0B10.2B9.5B9.3B11.2B10.0B
SG&A5.0B4.8B4.6B4.9B7.7B7.7B7.8B7.8B8.4B7.3B
Interest expense167.0M196.0M183.0M656.0M1.4B1.3B1.2B1.2B1.9B1.9B
Pretax income5.9B5.1B6.0B5.0B-6.9B8.1B7.7B8.4B-8.4B9.3B
Income tax1.4B4.2B1.0B1.5B2.1B1.1B1.4B400.0M554.0M2.3B
Net income4.5B1.0B4.9B3.4B-9.0B7.0B6.3B8.0B-8.9B7.1B
EPS (diluted)2.650.613.012.01-3.993.122.953.86-4.413.46
Diluted shares1.7B1.7B1.6B1.7B2.3B2.2B2.1B2.1B2.0B2.0B
Depreciation & amortization382.0M789.0M637.0M1.7B10.4B10.7B10.3B9.8B9.6B4.0B
Gross margin74.5%70.7%71.3%69.1%72.3%-----
Net margin22.9%4.8%21.8%13.2%-21.2%15.1%13.7%17.8%-18.5%14.6%
Revenue growth-+6.9%+8.6%+15.9%+62.6%+9.1%-0.5%-2.5%+7.3%-0.2%
EPS growth--77.0%+393%-33.2%-299%--5.4%+30.8%-214%-

Balance sheet

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash4.2B5.4B6.9B12.3B14.5B14.0B9.1B11.5B10.3B10.2B
Short-term investments2.1B1.4B1.8B3.0B1.3B3.0B130.0M816.0M513.0M464.0M
Receivables3.8B4.3B4.6B6.5B7.2B8.0B8.2B8.9B9.0B9.6B
Inventory1.2B1.2B1.2B4.3B2.1B2.1B2.3B2.7B2.6B2.7B
Current assets13.7B14.9B17.7B29.4B30.2B33.3B27.3B31.8B29.8B29.4B
Property & equipment5.0B5.0B5.0B6.3B5.9B6.0B6.3B6.6B7.1B7.5B
Goodwill6.9B6.9B6.5B22.5B20.5B20.5B21.1B21.2B21.7B21.8B
Total assets33.7B33.6B35.0B129.9B118.5B109.3B96.8B95.2B92.6B90.0B
Accounts payable1.7B2.2B1.9B2.4B2.7B2.9B3.0B3.3B3.6B3.6B
Current liabilities8.8B9.6B10.7B18.3B19.1B21.9B21.9B22.3B23.8B23.4B
Total debt6.6B7.3B6.9B49.5B52.7B49.3B43.2B39.5B51.5B47.1B
Total liabilities17.4B21.7B20.9B78.2B80.6B73.3B65.7B65.7B76.2B71.5B
Shareholders' equity16.2B11.7B14.0B51.6B37.8B35.9B31.1B29.4B16.3B18.5B
Retained earnings33.5B31.2B34.1B34.5B21.3B23.8B25.5B28.8B14.9B16.9B

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow3.1B5.3B7.1B8.2B14.1B16.2B13.1B13.9B15.2B14.2B
Capital spending1.2B1.1B951.0M836.0M753.0M973.0M1.1B1.2B1.2B1.3B
Free cash flow1.8B4.2B6.1B7.4B13.3B15.2B11.9B12.7B13.9B12.8B
Stock-based pay (added back)205.0M199.0M221.0M441.0M779.0M583.0M457.0M518.0M507.0M553.0M
Dividends paid2.5B2.6B2.6B2.7B4.1B4.4B4.6B4.7B4.9B5.0B
Buybacks231.0M2.5B320.0M7.3B1.5B6.3B8.0B5.2B00
Acquisitions359.0M726.0M2.4B24.8B13.1B1.6B4.3B1.2B21.8B3.9B
Debt raised01.5B026.8B6.9B05.9B4.5B12.9B5.7B
Debt repaid15.0M1.2B5.0M9.3B2.8B6.0B11.4B3.9B2.9B10.9B
Investing cash flow1.5B-66.0M-2.0B-9.9B-10.9B-538.0M-1.1B-2.3B-21.4B-4.1B
Financing cash flow-2.7B-4.1B-3.5B7.6B-1.2B-16.2B-17.0B-9.4B5.1B-10.3B
Dividend per share1.531.571.611.681.842.012.192.312.422.49

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)205.0M199.0M221.0M441.0M779.0M583.0M457.0M518.0M507.0M553.0M
Stock-based pay / revenue1.1%1.0%1.0%1.7%1.8%1.3%1.0%1.2%1.0%1.1%
Operating lease cost---115.0M194.0M220.0M224.0M317.0M290.0M293.0M
Operating lease cash paid---79.0M164.0M189.0M203.0M195.0M240.0M282.0M
Right-of-use assets--0704.0M859.0M919.0M1.2B1.4B1.2B1.6B
Operating lease liabilities--588.0M805.0M997.0M1.0B1.4B1.7B1.6B2.0B

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Work on BMY in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/BMY/export.csv") into a cell.